BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow grows to $295K
Q1 FY2026 financing cash flow was $295K, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $402.65M.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $295K or moves back toward the trailing-twelve-month quarterly average of $100.66M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 383.4M USD
- Year-over-year change
- +105.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 383.4M | +105.6% |
| FY2024 | 2024-12-31 | 186.46M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Financing Cash Flow vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1936.0% is the 3rd highest of 10, against a peer median of -32.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $974.19M USD | +23701.4% | +416.5% | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $402.65M USD | +1936.0% | — | — |
| LTM Aug 2026 | $261.21M USD | +28.6% | +26.8% | 37.2% | |
| LTM Sep 2026 | $187.21M USD | +12713.7% | +354.8% | — | |
| LTM Mar 2026 | CHF 105.86M CHF | -32.9% | +370.6% | 21003.4% | |
| LTM Mar 2026 | $105.09M USD | -24.9% | -25.7% | 74.8% | |
| LTM Mar 2026 | $102.81M USD | -191.7% | — | 44.2% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $80.93M USD | -73.5% | -61.7% | 84.1% |
| LTM Mar 2026 | $66.35M USD | -61.6% | — | 32.4% | |
| LTM Jun 2026 | $8.3M USD | -95.9% | +13.0% | 7.9% | |
| Peer median (excluding BBOT) | — | -32.9% | +26.8% | 44.2% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (74) | (3.52K) | (41.69K) | 7.6M | (134.04M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M |
| Change in Working Capital | 0 | 0 | 15K | (104.61K) | 6.43M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 172.52K | (1.84M) |
| Other Working Capital | 0 | 0 | 15K | (277.13K) | 8.27M |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | (8.53M) | 7.23M |
| Operating Cash Flow | 0 | 0 | (52.08M) | (763.82K) | (113.89M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (606K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (184M) | (83.93M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 157.86M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (184M) | 73.33M |
| Debt Repayment | 0 | 0 | 0 | (209.85K) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 187.25M | 395.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (578.55K) | (12.32M) |
| Financing Cash Flow | 0 | 0 | 0 | 186.46M | 383.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 0 | 225K | 1.7M | 342.84M |
| Free Cash Flow | 0 | 0 | (52.49M) | (763.82K) | (114.5M) |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.